ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Abril 26, 2022
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release … Class I) mutations in the CFTR gene using the Company’s Axiomer ® technology platform, and provide an update on other … Outubro 24, 2017
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release … intends to target these mutations using its proprietary Axiomer ® technology, which has shown compelling data in … Setembro 25, 2017
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Press release … develop any new product candidates, including through our Axiomer ® platform, that prior results observed from … Fevereiro 27, 2019